Nsc Therapeutics Gmbh

Jsw-Research Forschungslabor Gmbh

Manfred Windisch

Abraham Fisher

Nira Bar-Ner

Robert Wronski

Birgit Hutter-Paier

Nira Bar-ner

Provided are novel crystalline forms of a spiro-compound which acts as a muscarinic acetylcholine receptor agonist. In particular, isolated crystalline polymorphs of (S)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decane-3-one are described which have favorable properties in pharmaceutical manufacture. Also provided are methods to prepare said crystalline polymorphs, and to convert them into each other as well as methods for preparing medicaments containing the same which are suitable for use in the treatment of diseases and disorders that respond to modulation of the muscarinic acetylcholine receptor.

Crystalline polymorphs of a muscarinic acetylcholine receptor agonist

A peptidomimetic agent from dextrorotatory amino acids includes vGek with Dval-gly-Dglu-Dlys as a central D-amino acid sequence, whereby gly is equal to D-glycine, which is equal to L-glycine. Pharmaceutical agents for use in the treatment of neurodegenerative diseases, in particular Alzheimer's disease, Parkinson's disease, Lewy Body dementia, Creutzfeldt-Jakob disease, as well as Huntington's Chorea disease, multi-system atrophy as well as disorders similar to these neurodegenerative diseases that contain at least one peptidomimetic agent from dextrorotatory amino acids are also included.

Peptidomimetic agents from dextrorotatory amino acids as well as pharmaceutical agents that contain the latter for treatment of neurodegenerative diseases

Growing community of inventors

St. Radegund, Austria

Manfred Windisch